Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)

医学 内科学 疾病 重症监护医学 梅德林 血压 心脏病学 人口 糖尿病 心力衰竭
作者
Steven E. Nissen,Leslie Cho,Seth Frndak,Kathy Wolski,Jing Wang,Brian Manning,Eran Leitersdorf,Ulf Landmesser,Jackie McCluskey,Michael Joseph Blaha,Abraham Michael Lincoff,Ziqiang Zhao,Bjorn Mueller-Edenborn,Thomas G. Nuehrenberg,Sotirios Tsimikas,Anastasia Lesogor,Hui Cao,Vidyasagar Kalahasti,Ulrich Laufs,Seth J. Baum
出处
期刊:NEJM evidence [Massachusetts Medical Society]
卷期号:: EVIDoa2600373-EVIDoa2600373 被引量:1
标识
DOI:10.1056/evidoa2600373
摘要

BACKGROUND: Pelacarsen is an antisense oligonucleotide that reduces serum levels of lipoprotein(a). In a randomized placebo-controlled trial in patients with established cardiovascular disease, pelacarsen did not reduce the risk of major adverse cardiovascular events compared to placebo. We further investigated the association of pelacarsen treatment with cardiovascular outcomes. METHODS: We report the association of pelacarsen treatment with a primary composite end point of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization. Analyses included on-treatment, uninterrupted treatment, total primary end point events (first and recurrent events), landmark analyses classified by changes in and achieved lipoprotein(a) at 3 months, and key subgroups including baseline lipoprotein(a), low-density lipoprotein (LDL) cholesterol, high-sensitivity C-reactive protein (CRP), and time from qualifying event to enrollment. RESULTS: For participants on treatment, a primary end point occurred in 434 participants (10.4%) randomly assigned to placebo and 380 participants (9.1%) assigned to pelacarsen (hazard ratio, 0.98; 95% confidence interval [CI], 0.85 to 1.12). When evaluating participants with uninterrupted treatment, a primary end point event occurred in 167 participants (11.0%) in the pelacarsen group and 204 participants (10.1%) in the placebo group (hazard ratio, 1.09; 95% CI, 0.89 to 1.34). When evaluating total primary end point events, there were 644 events in the pelacarsen group and 646 events in the placebo group (rate ratio, 1.00; 95% CI, 0.87 to 1.14). In landmark analyses evaluating participants alive and free of the composite end point at 3 months, when compared to placebo there was no association between pelacarsen treatment and the primary end point either in participants with reduction in lipoprotein(a) greater than or equal to the median (170 nmol/l) (hazard ratio, 1.09; 95% CI, 0.92 to 1.29) or in participants who achieved lipoprotein(a) lower than or equal to the median (69.5 nmol/l) (hazard ratio, 1.10; 95% CI, 0.93 to 1.29). There was also no association between pelacarsen treatment and the primary end point in any of the evaluated key subgroups including classification by median baseline lipoprotein(a), LDL cholesterol, high-sensitivity CRP, or time from qualifying cardiovascular disease to enrollment. CONCLUSIONS: Pelacarsen was not associated with a reduction in major adverse cardiovascular events when evaluated by treatment exposure, changes in or achieved lipoprotein(a) levels at 3 months, considering total events, or within subgroups of baseline lipoprotein(a), LDL cholesterol, or high-sensitivity CRP levels.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI2S的应助被season采纳,获得30
1秒前
1秒前
斯文败类的应助被花筱一采纳,获得10
1秒前
科研通AI6.2的应助被张琼采纳,获得30
1秒前
颖zi发布了新的文献求助10
2秒前
zjt12345完成签到,获得积分10
2秒前
wtt0109完成签到,获得积分10
2秒前
cdercder的应助被日理万机采纳,获得10
2秒前
2秒前
美满的书南完成签到,获得积分10
2秒前
香蕉晓瑶发布了新的文献求助10
3秒前
xlb_szy完成签到,获得积分10
3秒前
无语的映发布了新的文献求助10
4秒前
HouKk发布了新的文献求助10
4秒前
Lily完成签到,获得积分10
4秒前
bkagyin的应助被11采纳,获得10
5秒前
biovhys发布了新的文献求助10
5秒前
bastien完成签到,获得积分10
5秒前
6秒前
朝与夕发布了新的文献求助10
6秒前
光亮雨发布了新的文献求助10
6秒前
xxt完成签到,获得积分20
7秒前
152455发布了新的文献求助10
7秒前
领导范儿的应助被liangxianli采纳,获得10
7秒前
小白小王完成签到,获得积分10
7秒前
香港下雪发布了新的文献求助10
8秒前
10秒前
11秒前
ding的应助被cjmlslddjd采纳,获得10
11秒前
Akim的应助被调皮彤采纳,获得10
11秒前
科研通AI6.2的应助被HouKk采纳,获得10
12秒前
13秒前
14秒前
研友_VZG7GZ的应助被loser采纳,获得10
14秒前
直率的问筠完成签到 ,获得积分10
15秒前
科研通AI6.2的应助被yue采纳,获得30
15秒前
丘比特的应助被星之雨采纳,获得30
16秒前
昏睡的曼巴完成签到,获得积分10
16秒前
arniu2008的应助被Adrenaline采纳,获得20
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170866
求助须知:如何正确求助?哪些是违规求助? 9563691
关于积分的说明 21771699
捐赠科研通 7762353
什么是DOI,文献DOI怎么找? 3430767
关于科研通互助平台的介绍 2554622
邀请新用户注册赠送积分活动 2475597